Search

everythinglearnresearchcommunity

for

Search:↓

A user has been using dutasteride, RU58841, minoxidil, and ketoconazole for 2 years with no progress and worsening hair recession. They seek advice on how to proceed.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

The user experienced significant hair regrowth using 0.5 mg Dutasteride and 5 mg oral Minoxidil daily, after initially using finasteride and a lower dose of Minoxidil. They are considering dermarolling or derma stamping to improve results further before opting for a hair transplant.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

User tried topical finasteride mixed with minoxidil, Nizoral shampoo, oral minoxidil, and FUE hair transplant for hair loss. User asks when it's safe to trim hair after transplant and considers trying RU58841 or pyrilutamide.

The user is considering starting pyrilutamide before a scheduled hair transplant, having previously used oral minoxidil and finasteride with worsening results. They also tried dutasteride, which worsened their hair and made their skin oily.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.

A 28-year-old male experiencing diffuse thinning and miniaturization around the ears and back has tried finasteride, dutasteride, and both topical and oral minoxidil without success. He is seeking advice on identifying the type of hair loss and next steps since current treatments are ineffective.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

Clascoterone 5% shows potential for hair thickening and darkening, especially when combined with treatments like finasteride. It may be a good alternative for those who experience side effects from other treatments.

The user was diagnosed with DUPA and initially treated with finasteride, then switched to dutasteride which worsened their hair loss. They are now returning to finasteride and adding treatments including oral minoxidil, Proscar, Viviscal, pumpkin seed oil, LLLT, and Nizoral shampoo, hoping for hair regrowth.

A user who experienced positive results from using finasteride and dutasteride to treat their hair loss, with 2000 grafts being transplanted in the temples area for further improvement. They also discussed cost and other treatments such as minoxidil.

A 23-year-old male has been using oral finasteride and topical minoxidil for 14 months, along with derma stamping and vitamins, but is considering switching to dutasteride due to dissatisfaction with progress. Users suggest cutting hair shorter to better track progress, and some recommend adding dutasteride and possibly a hair transplant in the future.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A 24-year-old male experienced significant hair regrowth after 14 months of treatment with 0.5mg dutasteride and 5mg minoxidil, with no side effects reported. He plans to consider a hair transplant for his hairline, as the treatment did not improve that area.

Rosemary-lavender oil can stimulate hair growth compared to a placebo. Some users combine it with treatments like dutasteride, minoxidil, and RU58841.

The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.

The user is using a hair recovery treatment with 0.5 mg dutasteride, 5 mg biotin, 5% topical minoxidil, and dermarolling twice a week. They are considering using a 1.5 mm dermaroller and red light therapy.

A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.

The conversation discusses using RU58841, a research chemical, for hair loss treatment. The user plans to use it due to side effects from finasteride and minoxidil, despite skepticism about its effectiveness and lack of FDA approval.

A 22-year-old male shares his 2-month progress using a regimen of 0.5mg dutasteride daily, 1.5mm dermarolling weekly, a daily multivitamin, and a topical serum with 10% minoxidil and 0.1% finasteride. He reports impressive hair regrowth, especially at the hairline, and has experienced no sexual side effects.

After nearly four months on finasteride, a user noticed improved hair quality but developed nipple puffiness, suggesting early signs of gynecomastia. They considered switching to other treatments like CB-03-01 or RU58841 and contemplated consulting an endocrinologist about aromatase inhibitors.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

Hair loss discussion involved Finasteride, Minoxidil, and RU58841. User experienced sudden shedding after 1.5 years of Finasteride and Minoxidil use, seeking advice.

The user stopped using finasteride due to side effects and is considering Fluridil (Eucapil) as an alternative for hair loss treatment. They are exploring other options like RU58841 and are interested in the experiences of others with Fluridil, noting its good safety profile despite the cost.

The conversation discusses the hair loss treatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.

A user reports significant hair shedding and regrowth after increasing their dutasteride dosage to 5mg, alongside using RU58841, minoxidil, and topical finasteride, with no side effects. They recommend high doses of dutasteride, sourced from China, despite concerns about its safety.

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.